Kidder Stephen W grew its position in Novartis AG (NYSE:NVS) by 1.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 87,954 shares of the company’s stock after buying an additional 1,080 shares during the period. Novartis accounts for about 2.5% of Kidder Stephen W’s portfolio, making the stock its 15th largest position. Kidder Stephen W’s holdings in Novartis were worth $6,644,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P boosted its holdings in shares of Novartis by 12.8% in the 1st quarter. Loomis Sayles & Co. L P now owns 7,802,086 shares of the company’s stock valued at $630,799,000 after buying an additional 887,198 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Novartis by 4.5% in the 2nd quarter. Fisher Asset Management LLC now owns 7,325,261 shares of the company’s stock valued at $553,350,000 after buying an additional 318,787 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Novartis by 2.3% in the 1st quarter. Northern Trust Corp now owns 4,089,571 shares of the company’s stock valued at $330,642,000 after buying an additional 90,010 shares in the last quarter. Thomaspartners Inc. boosted its holdings in shares of Novartis by 3.0% in the 1st quarter. Thomaspartners Inc. now owns 3,842,741 shares of the company’s stock valued at $310,686,000 after buying an additional 110,361 shares in the last quarter. Finally, Aristotle Capital Management LLC boosted its holdings in shares of Novartis by 6.4% in the 1st quarter. Aristotle Capital Management LLC now owns 3,399,641 shares of the company’s stock valued at $274,861,000 after buying an additional 204,507 shares in the last quarter. Institutional investors and hedge funds own 10.92% of the company’s stock.
A number of analysts have recently weighed in on the stock. Deutsche Bank restated a “neutral” rating on shares of Novartis in a report on Tuesday, April 10th. Barclays upgraded shares of Novartis from an “underweight” rating to an “equal weight” rating in a report on Thursday, July 19th. DZ Bank restated a “buy” rating on shares of Novartis in a report on Thursday, July 19th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, July 19th. Finally, ValuEngine upgraded shares of Novartis from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 19th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $92.33.
NVS stock traded up $0.26 during trading on Monday, reaching $83.75. The company had a trading volume of 55,812 shares, compared to its average volume of 2,103,315. The stock has a market capitalization of $193.48 billion, a PE ratio of 17.42, a price-to-earnings-growth ratio of 1.87 and a beta of 0.75. The company has a quick ratio of 0.89, a current ratio of 1.15 and a debt-to-equity ratio of 0.30. Novartis AG has a twelve month low of $72.30 and a twelve month high of $94.19.
Novartis (NYSE:NVS) last released its earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.02. The company had revenue of $13.16 billion during the quarter, compared to analysts’ expectations of $12.93 billion. Novartis had a net margin of 27.06% and a return on equity of 16.05%. Novartis’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the business earned $1.22 EPS. equities research analysts expect that Novartis AG will post 5.04 earnings per share for the current year.
In related news, major shareholder Bioventures Ltd Novartis sold 12,460 shares of Novartis stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $3.84, for a total value of $47,846.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 43,360 shares of company stock valued at $179,441 over the last quarter. 0.01% of the stock is owned by company insiders.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
See Also: Short Selling
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.